Literature DB >> 12173817

Impact of cardiac surgery using cardiopulmonary bypass on course of chronic lymphatic leukemia: a case-control study.

Evgenij V Potapov1, Heinz R Zurbrügg, Corinna Herzke, Stefanie Srock, Hanno Riess, Ralf Sodian, Sabine Hübler, Roland Hetzer.   

Abstract

BACKGROUND: Chronic lymphatic leukemia (CLL) is a common disease among elderly individuals. The number of older patients undergoing operations with cardiopulmonary bypass (CPB) is increasing. The aim of the present study was to evaluate the impact of cardiac surgery using CPB on the long-term course of CLL.
METHODS: From 1992 to 2000, a total of 28 patients with CLL underwent heart surgery using CPB at our institution (group I). These patients were compared with 25 patients from the CLL register who were retrospectively matched with regard to preoperative administration of chemotherapy, Binet classification, age, and sex (group II). A time-point was selected for each patient in group II so that the variables for the two groups corresponded in relation to the time of operation of the patients in group I. Midterm follow-up data in both groups were analyzed.
RESULTS: There were no differences between groups regarding matched variables. The mean follow-up time was similar in both groups (2.6 +/- 2.2 vs 2.3 +/- 1.3 years, p > 0.5). The 30-day mortality in group I was 14.3%. The mean stay in the intensive care unit was 4.2 +/- 7.5 days; the median number of units of packed red blood cells transfused was three (range 0 to 17). Compared with group II, in group I significantly fewer patients (11 vs 17, p = 0.049) required chemotherapy significantly later (1.98 +/- 2.06 vs 0.84 +/- 1.18 years, p = 0.018). During follow-up, no difference was found between groups regarding severe infections (10 vs 14, p = 0.14). Despite postoperative mortality in group I, the long-term mortality was similar in both groups (p = 0.3).
CONCLUSIONS: Cardiac surgery using CPB did not have a negative impact on the natural course of CLL. Moreover, this procedure seems to be associated with a decrease in the number of postoperative chemotherapy administrations and with an increase of chemotherapy-free survival time. Although CLL may be a risk factor in the early postoperative period, it is not a contraindication for cardiac surgery using CPB.

Entities:  

Mesh:

Year:  2002        PMID: 12173817     DOI: 10.1016/s0003-4975(02)03678-0

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  4 in total

1.  Acute leukaemoid reaction following cardiac surgery.

Authors:  Nigel E Drury; Ayyaz Ali; Shafi Mussa; Stephen T Webb; Kanchan P Rege; John Wallwork
Journal:  J Cardiothorac Surg       Date:  2007-01-09       Impact factor: 1.637

2.  Mitral valve repair facilitated with transapical beating heart NeoChord implantation in a non-Hodgkin's lymphoma patient.

Authors:  Ali Sait Kavakli; Raif Umut Ayoglu; Nilgun Kavrut Ozturk; Omer Haldun Tekinalp; Zehra Erkal; Kerem Inanoglu; Mustafa Emmiler
Journal:  J Anesth       Date:  2016-09-19       Impact factor: 2.078

3.  Urgent Coronary Artery Bypass Surgery in a Patient with Postinfarction Angina and Active Myelomonocytic Leukaemia.

Authors:  Samuel Anthony Galea; Joseph Galea
Journal:  Case Rep Oncol       Date:  2016-11-18

4.  Use of Tocilizumab in Management of Post-Operative Myelomonocytic Leukemoid Reaction.

Authors:  Megan Melody; Emily Butts; David Menke; Kevin Landolfo; Keith Oken; Taimur Sher; Sharad Khurana
Journal:  Leuk Res Rep       Date:  2020-11-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.